+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combination of BNT324, a B7-H3 antibody-drug conjugate, with BNT327, a bispecific antibody targeting PD-L1 and VEGF, in adults with advanced or metastatic small cell lung cancer SCLC and non-small cell lung cancer NSCLC. This two-part Phase IbII trial aims to find safe dose levels, optimize dosing, and assess preliminary efficacy and safety in various lung cancer patient groups. Participants in Part 1 receive escalating doses of BNT324 with BNT327 to determine recommended dose levels. Part 2 compares these dose levels in randomized cohorts of treatment-naive NSCLC and relapsed SCLC patients, with additional cohorts receiving the optimal dose to further evaluate efficacy and safety. Treatments are given via intravenous infusion, and dosing is adjusted based on safety and response data. Throughout the study, participants undergo screening, treatment, safety follow-up, and long-term survival monitoring. Researchers assess dose-limiting toxicities, adverse events, objective response rates, disease control, progression-free survival, and overall survival. Treatment effects are evaluated up to 87 months, with close monitoring for side effects and treatment tolerability during and after therapy.

Age: 18Years +All GendersPhase 1Phase 2
91 locations
T

Actively Recruiting

Researchers are evaluating a new tuberculosis preventive treatment among adolescents and school staff who have been in close contact with active TB cases. This study compares a novel 1-month ultra-short regimen called 1H3P3 with the standard 3-month 3HR regimen, aiming to prevent latent TB infection from progressing to active tuberculosis. The trial is a phase 3, multi-center, open-label, cluster randomized controlled study conducted in school settings in China, with the goal of improving TB prevention strategies for adolescents. Participants are randomly assigned to receive either the 12-dose 1H3P3 regimen of isoniazid and rifapentine taken three times a week for one month, or the 3HR regimen of isoniazid and rifampicin taken once daily for three months. Close contacts of TB cases are screened using blood tests, chest X-rays, sputum testing, and symptom checks to rule out active TB before enrollment. The treatment period lasts either one or three months depending on the group, followed by two years of follow-up to monitor for TB development. During the study, participants will undergo regular assessments including monitoring for active tuberculosis through clinical and laboratory tests, adverse events, treatment adherence, and drug resistance if active TB occurs. The main measurement is the cumulative incidence of active TB over 24 months after treatment begins. Safety and treatment completion rates are tracked throughout. Participation involves screening, treatment administration, and periodic follow-up visits over two years to evaluate outcomes and overall TB prevention effectiveness.

Age: 13Years +All GendersPhase 3
66 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a combination treatment including surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine compared to nab-paclitaxel plus gemcitabine alone as the first treatment for people with metastatic pancreatic cancer. This phase IIIII multicenter trial aims to understand which therapy may work better for this stage of pancreatic cancer. Participants will be randomly assigned to receive either the combination of surufatinib 200mg daily, camrelizumab 200mg intravenous drip every 3 weeks on day 1, nab-paclitaxel 125 mgm2 intravenous drip on days 1 and 8, and gemcitabine 1000 mgm2 intravenous drip on days 1 and 8 or the standard treatment of nab-paclitaxel plus gemcitabine on the same schedule. Another group receives surufatinib with nab-paclitaxel and gemcitabine. Treatments continue according to protocol as first-line therapy. Participants will be monitored through regular visits where researchers assess overall survival, progression-free survival, tumor response, and quality of life using questionnaires. Assessments will occur up to about 20 months from the first dose, including scans and evaluations of symptoms. Safety, side effects, and treatment adherence will also be closely followed during the trial.

Age: 18Years - 75YearsAll GendersPhase 2Phase 3
52 locations
S

Actively Recruiting

Researchers are studying the rate of Mycobacterium tuberculosis MTB infection among students who have been in close contact with active tuberculosis ATB patients at school. The study also aims to identify risk factors related to tuberculosis infection and evaluate the health economics of the screening strategy. This observational study is sponsored by Huashan Hospital and focuses on school contacts of ATB patients aged 13 years and older. Participants will undergo the QuantiFERON-TB Gold QFT test to determine if they have been infected with MTB. Those who test positive will have further assessments including sputum Xpert MTBRIF testing, physical examination, chest CT scan, and if necessary, sputum culture to differentiate latent TB infection from active tuberculosis. For participants over 15 years old with a positive QFT result, a chest X-ray scan may also be performed. During the study, participants will provide baseline information including age, sex, vaccination history, contact patterns, and medical history through checklists. Researchers will monitor the prevalence of tuberculosis infection at baseline and collect other relevant data. The study is observational, meaning no treatment is provided, and participants will be followed to understand the infection status and related factors. The total study duration extends until the end of 2025.

Age: 13Years +All Genders
44 locations
C

Actively Recruiting

Colorectal cancer CRC is a common and growing health concern in China, with its incidence increasing faster than the global average. Early detection through screening is crucial to reduce the disease burden, especially in average risk populations where most sporadic cases occur. This trial aims to compare different colorectal cancer screening methods to find effective approaches for the average risk population in China. Participants will be randomly assigned to one of three screening groups a colonoscopy group that receives a single colonoscopy in the first year a FIT group that undergoes annual fecal immunochemical tests for four years, with positive results followed by diagnostic colonoscopy and a FIT plus blood test group that combines annual FIT and blood tests detecting cfDNA methylation, also followed by colonoscopy if positive. All groups will have suspicious lesions removed and examined, followed by annual follow-ups and long-term monitoring. During the study, participants will provide fecal, blood, and tissue samples. Researchers will assess colorectal cancer mortality over 10 years as the primary outcome, along with detection rates of advanced lesions, population compliance, cancer stages, incidence rates, quality of life, and cost-effectiveness over 4 to 10 years. This comprehensive approach includes a 4-year screening phase and extended follow-up to monitor outcomes and safety.

Age: 45Years - 74YearsAll GendersPhase Not Applicable
7 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TQB6411 Injection in adults with recurrent or metastatic esophageal cancer who have not responded to prior treatment with PD-1PD-L1 inhibitors combined with platinum-based chemotherapy. This study includes both Phase Ib, focusing on safety and tolerance, and Phase II, which assesses how well the treatment works in this patient group. Participants receive TQB6411 Injection in treatment cycles lasting either 21 or 28 days. TQB6411 is an antibody-drug conjugate targeting specific proteins EGFR and c-Met involved in cancer growth. The treatment is given continuously during the study period to evaluate its effects and safety. During the trial, participants will have regular assessments including tumor measurements, blood tests, and monitoring for side effects over a period of up to 24 months. Researchers will measure outcomes such as recommended dose, adverse events, progression-free survival, response rates, and overall survival. Additional tests will evaluate drug concentration in the blood and immune responses to the treatment. Participants will be closely monitored for safety throughout the study duration.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
30 locations
C

Actively Recruiting

Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer that has an ESR1 mutation. This study focuses on patients who have previously received ribociclib or palbociclib-based treatment and aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants will receive either 5 mg per day of oral lasofoxifene plus oral abemaciclib 150 mg twice daily, or fulvestrant 500 mg given intramuscularly on Days 1, 15, and 29, then once monthly thereafter, combined with oral abemaciclib 150 mg twice daily. The study is randomized and open-label, allowing comparison between these two treatment combinations over time. During the study, participants will be closely monitored for progression-free survival, objective response rate, overall survival, clinical benefit rate, duration and time to response, time to cytotoxic chemotherapy, quality of life using a specific breast cancer assessment tool, and the incidence of adverse events. The study includes various assessments and safety monitoring over approximately three years to evaluate these outcomes and the participants response to the treatments.

Age: 18Years +All GendersPhase 3
224 locations